Hjem › Prostatakræft › Oklahoma
Prostatakræft kliniske forsøg i Oklahoma
24 studier for Prostatakræft søger deltagere på steder i Oklahoma.
Byer i Oklahoma
Officiel studietekst (engelsk)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04585750Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 2. okt. 2026 · NCT06931340Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06632977Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT03866382Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- Oklahoma Proton Center, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 29. sep. 2026 · NCT01492972Protoacoustic Imaging For 3D Mapping
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07832617A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Hightower Clinical, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 22. sep. 2026 · NCT07213674Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Utica Park Urology, Tulsa
Rekrutterer
Alder 18 og opefter · Mænd · Opdateret 14. sep. 2026 · NCT06511141Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Urologic Specialists, Tulsa
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 11. sep. 2026 · NCT06056830Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 10. sep. 2026 · NCT05946213The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFrivillige med god helbredstilstand velkomne
Alder 45 til 75 · Alle køn · Opdateret 2. sep. 2026 · NCT06995898Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererObservationsstudie
Alder 18 til 100 · Mænd · Opdateret 26. aug. 2026 · NCT06960798Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 19. aug. 2026 · NCT04423211A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 7. aug. 2026 · NCT06751329Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 14. jul. 2026 · NCT06592924Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
- University of Oklahoma HSC, Oklahoma City
Rekrutterer
Alder 18 og opefter · Mænd · Opdateret 1. apr. 2026 · NCT06651359Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Mænd · Opdateret 29. jan. 2026 · NCT05806515Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 22. jan. 2026 · NCT06470243Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 17. dec. 2025 · NCT07014618SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Connect2Care: Prostate Cancer Education and Screenings for African American Men
- TSET Health Promotion Research Center, Oklahoma City
Rekrutterer
Alder 45 til 69 · Mænd · Opdateret 25. sep. 2025 · NCT07055165Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 11. sep. 2025 · NCT03678025A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Exelixis Clinical Site #13, Oklahoma City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. sep. 2025 · NCT05932862Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.